Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib PK in Severe Hepatic Impairment
NCT03865446Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2019
- Primary completion
- Oct 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dacomitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time. Started Apr 2019; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03865446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03865446.